GILEAD SCIENCES, INC. Cost of Revenue
GILEAD SCIENCES, INC. (GILD) reported Cost of Revenue of $1.58 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- GILEAD SCIENCES, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $1.58B, a 5.20% increase year-over-year.
- GILEAD SCIENCES, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $1.45B, a 6.17% decline year-over-year.
- GILEAD SCIENCES, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $1.62B, a 2.72% increase year-over-year.
- GILEAD SCIENCES, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $1.57B, a 0.32% decline year-over-year.
- GILEAD SCIENCES, INC. cost of goods and services sold for fiscal 2025 was $6.23B, a 0.27% decline from fiscal 2024.
- GILEAD SCIENCES, INC. cost of goods and services sold for fiscal 2024 was $6.25B, a 3.80% decline from fiscal 2023.
- GILEAD SCIENCES, INC. cost of goods and services sold for fiscal 2023 was $6.50B, a 14.87% increase from fiscal 2022.
- GILEAD SCIENCES, INC. cost of goods and services sold for fiscal 2022 was $5.66B, a 14.30% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.58B 10-Q · filed 2026-08-06 | $3.02B 10-Q · filed 2026-08-06 | $4.65B derived: sum of 3 quarters · filed 2026-08-06 | $6.22B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.45B 10-Q · filed 2026-05-07 | $3.07B derived: sum of 2 quarters · filed 2026-05-07 | $4.64B derived: sum of 3 quarters · filed 2026-05-07 | $6.14B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.62B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.19B derived: sum of 2 quarters · filed 2026-02-24 | $4.69B derived: sum of 3 quarters · filed 2026-08-06 | $6.23B 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.57B 10-Q · filed 2025-11-07 | $3.07B derived: sum of 2 quarters · filed 2026-08-06 | $4.61B 10-Q · filed 2025-11-07 | $6.19B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.50B 10-Q · filed 2026-08-06 | $3.04B 10-Q · filed 2026-08-06 | $4.62B derived: sum of 3 quarters · filed 2026-08-06 | $6.20B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.54B 10-Q · filed 2026-05-07 | $3.12B derived: sum of 2 quarters · filed 2026-05-07 | $4.70B derived: sum of 3 quarters · filed 2026-05-07 | $6.24B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.58B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.15B derived: sum of 2 quarters · filed 2026-02-24 | $4.70B derived: sum of 3 quarters · filed 2026-02-24 | $6.25B 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.57B 10-Q · filed 2025-11-07 | $3.12B derived: sum of 2 quarters · filed 2025-11-07 | $4.67B 10-Q · filed 2025-11-07 | $6.76B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.54B 10-Q · filed 2025-08-07 | $3.10B 10-Q · filed 2025-08-07 | $5.19B derived: sum of 3 quarters · filed 2026-02-24 | $6.75B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $1.55B 10-Q · filed 2025-05-07 | $3.64B derived: sum of 2 quarters · filed 2026-02-24 | $5.21B derived: sum of 3 quarters · filed 2026-02-24 | $6.65B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $2.09B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.65B derived: sum of 2 quarters · filed 2026-02-24 | $5.10B derived: sum of 3 quarters · filed 2026-02-24 | $6.50B 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.56B 10-Q · filed 2024-11-12 | $3.01B derived: sum of 2 quarters · filed 2024-11-12 | $4.41B 10-Q · filed 2024-11-12 | $5.80B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $1.44B 10-Q · filed 2024-08-08 | $2.84B 10-Q · filed 2024-08-08 | $4.24B derived: sum of 3 quarters · filed 2025-02-28 | $5.63B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $1.40B 10-Q · filed 2024-05-08 | $2.80B derived: sum of 2 quarters · filed 2025-02-28 | $4.19B derived: sum of 3 quarters · filed 2025-02-28 | $5.63B derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $1.40B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $2.79B derived: sum of 2 quarters · filed 2025-02-28 | $4.23B derived: sum of 3 quarters · filed 2025-02-28 | $5.66B 10-K · filed 2025-02-28 |
| 2022-09-30 | $1.40B 10-Q · filed 2023-11-07 | $2.84B derived: sum of 2 quarters · filed 2023-11-07 | $4.26B 10-Q · filed 2023-11-07 | $6.89B derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | $1.44B 10-Q · filed 2023-08-04 | $2.87B 10-Q · filed 2023-08-04 | $5.49B derived: sum of 3 quarters · filed 2024-02-23 | $6.72B derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $1.42B 10-Q · filed 2023-05-03 | $4.05B derived: sum of 2 quarters · filed 2024-02-23 | $5.27B derived: sum of 3 quarters · filed 2024-02-23 | $6.66B derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $2.63B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $3.85B derived: sum of 2 quarters · filed 2024-02-23 | $5.24B derived: sum of 3 quarters · filed 2024-02-23 | $6.60B 10-K · filed 2024-02-23 |
| 2021-09-30 | $1.22B 10-Q · filed 2022-11-02 | $2.61B derived: sum of 2 quarters · filed 2022-11-02 | $3.97B 10-Q · filed 2022-11-02 | $5.37B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $1.39B 10-Q · filed 2022-08-08 | $2.75B 10-Q · filed 2022-08-08 | $4.15B derived: sum of 3 quarters · filed 2023-02-22 | $5.29B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $1.36B 10-Q · filed 2022-05-04 | $2.76B derived: sum of 2 quarters · filed 2023-02-22 | $3.90B derived: sum of 3 quarters · filed 2023-02-22 | $4.96B derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $1.40B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $2.54B derived: sum of 2 quarters · filed 2023-02-22 | $3.60B derived: sum of 3 quarters · filed 2023-02-22 | $4.57B 10-K · filed 2023-02-22 |
| 2020-09-30 | $1.14B 10-Q · filed 2021-11-03 | $2.21B derived: sum of 2 quarters · filed 2021-11-03 | $3.17B 10-Q · filed 2021-11-03 | $4.86B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $1.06B 10-Q · filed 2021-08-05 | $2.03B 10-Q · filed 2021-08-05 | $3.72B derived: sum of 3 quarters · filed 2022-02-23 | $4.75B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $969.00M 10-Q · filed 2021-05-06 | $2.65B derived: sum of 2 quarters · filed 2022-02-23 | $3.69B derived: sum of 3 quarters · filed 2022-02-23 | $4.69B derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $1.68B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $2.72B derived: sum of 2 quarters · filed 2022-02-23 | $3.72B derived: sum of 3 quarters · filed 2022-02-23 | $4.67B 10-K · filed 2022-02-23 |
| 2019-09-30 | $1.03B 10-Q · filed 2020-11-04 | $2.04B derived: sum of 2 quarters · filed 2020-11-04 | $2.99B 10-Q · filed 2020-11-04 | $4.56B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $1.00B 10-Q · filed 2020-08-06 | $1.96B 10-Q · filed 2020-08-06 | $3.53B derived: sum of 3 quarters · filed 2021-02-25 | $4.61B derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $957.00M 10-Q · filed 2020-05-06 | $2.53B derived: sum of 2 quarters · filed 2021-02-25 | $3.61B derived: sum of 3 quarters · filed 2021-02-25 | $4.81B derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $1.57B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.66B derived: sum of 2 quarters · filed 2021-02-25 | $3.85B derived: sum of 3 quarters · filed 2021-02-25 | $4.85B 10-K · filed 2021-02-25 |
| 2018-09-30 | $1.09B 10-Q · filed 2019-11-05 | $2.28B derived: sum of 2 quarters · filed 2019-11-05 | $3.28B 10-Q · filed 2019-11-05 | $4.54B derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $1.20B 10-Q · filed 2019-08-06 | $2.20B 10-Q · filed 2019-08-06 | $3.45B derived: sum of 3 quarters · filed 2020-02-25 | $4.49B derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $1.00B 10-Q · filed 2019-05-08 | $2.26B derived: sum of 2 quarters · filed 2020-02-25 | $3.29B derived: sum of 3 quarters · filed 2020-02-25 | $4.42B derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $1.26B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $2.29B derived: sum of 2 quarters · filed 2020-02-25 | $3.41B derived: sum of 3 quarters · filed 2020-02-25 | $4.37B 10-K · filed 2020-02-25 |
| 2017-09-30 | $1.03B 10-Q · filed 2018-11-06 | $2.16B derived: sum of 2 quarters · filed 2018-11-06 | $3.12B 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $1.13B 10-Q · filed 2018-08-06 | $2.08B 10-Q · filed 2018-08-06 | ||
| 2016-12-31 | $4.26B 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |